WallStSmart

Aveanna Healthcare Holdings Inc (AVAH)vsAstraZeneca PLC (AZN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 2258% more annual revenue ($61.37B vs $2.60B). AZN leads profitability with a 17.0% profit margin vs 10.6%. AVAH trades at a lower P/E of 10.7x. AVAH earns a higher WallStSmart Score of 61/100 (C+).

AVAH

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 5.7Quality: 3.5
Piotroski: 4/9Altman Z: 0.95

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVAHSignificantly Overvalued (-70.9%)

Margin of Safety

-70.9%

Fair Value

$4.67

Current Price

$12.41

$7.74 premium

UndervaluedFair: $4.67Overvalued
AZNUndervalued (+15.2%)

Margin of Safety

+15.2%

Fair Value

$195.81

Current Price

$166.58

$29.23 discount

UndervaluedFair: $195.81Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVAH3 strengths · Avg: 9.3/10
P/E RatioValuation
10.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

EPS GrowthGrowth
38.5%8/10

Earnings expanding 38.5% YoY

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$257.57B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

Areas to Watch

AVAH3 concerns · Avg: 2.3/10
Price/BookValuation
9.4x4/10

Trading at 9.4x book value

Altman Z-ScoreHealth
0.952/10

Distress zone — elevated risk

Debt/EquityHealth
5.241/10

Elevated debt levels

AZN2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AVAH

The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bear Case : AVAH

The primary concerns for AVAH are Price/Book, Altman Z-Score, Debt/Equity. Debt-to-equity of 5.24 is elevated, increasing financial risk.

Bear Case : AZN

The primary concerns for AZN are EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

AVAH profiles as a value stock while AZN is a mature play — different risk/reward profiles.

AVAH carries more volatility with a beta of 1.97 — expect wider price swings.

AVAH is growing revenue faster at 13.7% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AVAH scores higher overall (61/100 vs 60/100) and 13.7% revenue growth. AZN offers better value entry with a 15.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aveanna Healthcare Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?